This somatic JAK2 mutation V617F is known to have been reported in most patients with polycythemia vera (PV), as well as in approximately one-third of patients with essential thrombocythemia and or idiopathic myelofibrosis [40]. This evidence concerns the gene JAK2 and primary myelofibrosis.